SEARCH

SEARCH BY CITATION

References

  • Abraham, D.J., Mehanna, A.S., Wireko, F.C., Whitney, J., Thomas, R.P. & Orringer, E.P. (1991) Vanillin, a potential agent for the treatment of sickle cell anemia. Blood, 77, 13341341.
  • Aruoma, O.I. (1992) Dietary management of sickle cell anemia with vanillin. Free Radical Research Communication, 17, 349352.
  • Asakura, T. & Mayberry, J. (1984) Relationship between morphologic characteristics of sickle cells and method of deoxygenation. Journal of Laboratory and Clinical Medicine, 104, 987994.
  • Asakura, T., Mattiello, J.A., Obata, K., Asakura, K., Reilly, M.P., Tomassini, N., Schwartz, E. & Ohene-Frempong, K. (1994) Partially oxygenated sickled cells: sickle-shaped red cells found in circulating blood of patients with sickle cell disease. Proceedings of the National Academy of Sciences of the United States of America, 91, 1258912593.
  • Beddell, C.R., Goodford, P.J., Kneen, G., White, R.D., Wilkinson, S. & Wootton, R. (1984) Substituted benzaldehydes designed to increase the oxygen affinity of human haemoglobin and inhibit the sickling of sickle erythrocytes. British Journal of Pharmacology, 82, 397407.
  • Bunn, H.F. & Forget, B.G. (1986) Sickle cell disease – clinical and epidemiological aspects. In: Hemoglobin: Molecular, Genetic and Clinical Aspects, p. 5023. Saunders, Philadelphia.
  • Charache, S. (1997) Mechanism of action of hydroxyurea in the management of sickle cell anemia in adults. Seminars in Hematology, 34, 1521.
  • Eaton, W.A. & Hofrichter, J. (1990) Sickle cell hemoglobin polymerization. Advances in Protein Chemistry, 40, 63279.
  • Embury, S.H., Hebbel, R.P., Mohandas, N. & Steinberg, M.H. (1994) Sickle Cell Disease: Basic Principles and Clinical Practice. Lippincott-Ravin, Philadelphia/New York.
  • Farthing, D., Sica, D., Abernathy, C., Fakhry, I., Roberts, J.D., Abraham, D.J. & Swerdlow, P. (1999) High-performance liquid chromatographic method for determination of vanillin and vanillic acid in human plasma, red blood cells and urine. Journal of Chromatography. B. Biomedical Sciences and Applications, 726, 303307.
  • Fitzharris, P., McLean, A.E., Sparks, R.G., Weatherley, B.C., White, R.D. & Wootton, R. (1985) The effects in volunteers of BW12C, a compound designed to left-shift the blood-oxygen saturation curve. British Journal of Clinical Pharmacology, 19, 471481.
  • Goldberg, M.A., Brugnara, C., Dover, G.J., Schapira, L., Lacroix, L. & Bunn, H.F. (1992) Hydroxyurea and erythropoietin therapy in sickle cell anemia. Seminars in Oncology, 19, 7481.
  • Hasley, C. & Roberts, I.A. (2003) The role of hydroxyurea in sickle cell disease. British Journal of Haematology, 120, 177186.
  • Hebbel, R.P. (1991) Beyond hemoglobin polymerization: the red blood cell membrane and sickle disease pathophysiology. Blood, 77, 214237.
  • Horiuchi, K., Ohata, J., Hirano, Y. & Asakura, T. (1990) Morphologic studies of sickle erythrocytes by image analysis. Journal of Laboratory and Clinical Medicine, 115, 613620.
  • Horiuchi, K., Onyike, A.E. & Osterhout, M.L. (1996) Sickling in vitro of reticulocytes from patients with sickle cell disease at venous oxygen tension. Experimental Hematology, 24, 6876.
  • Ingram, V.M. (1956) A specific chemical difference between the globins of normal human and sickle-cell anaemia haemoglobin. Nature, 178, 792794.
  • Iyamu, E.W., Turner, E.A. & Asakura, T. (2002) In vitro effects of NIPRISAN (Nix-0699): a naturally occurring, potent antisickling agent. British Journal of Haematology, 118, 337343.
  • Iyamu, E.W., Turner, E.A. & Asakura, T. (2003) Niprisan (Nix-0699) improves the survival rates of transgenic sickle cell mice under acute severe hypoxic conditions. British Journal of Haematology, 122, 10011008.
  • Jenner, P., Hagan, E., Taylor, J.M., Cook, E.L. & Fitzhugh, O.G. (1964) Food flavourings and compounds of related structure I. Acute oral toxicity. Food and Cosmetics Toxicology, 2, 327343.
  • Keidan, A.J., Franklin, I.M., White, R.D., Joy, M., Huehns, E.R. & Stuart, J. (1986) Effect of BW12C on oxygen affinity of haemoglobin in sickle-cell disease. Lancet, 1, 831834.
  • Merrett, M., Stammers, D.K., White, R.D., Wootton, R. & Kneen, G. (1986) Characterization of the binding of the anti-sickling compound, BW12C, to haemoglobin. Biochemical Journal, 239, 387392.
  • National Institutes of Health (1985) Guide for the Care and Use of Laboratory Animals, Publication No. 86–23. United States Department of Health and Human Services, National Institutes of Health, Bethseda, MD (revised 1985).
  • Platt, O.S., Brambilla, D.J., Rosse, W.F., Milner, P.F., Castro, O., Steinberg, M.H. & Klug, P.P. (1994) Mortality in sickle cell disease. Life expectancy and risk factors for early death. New England Journal of Medicine, 330, 16391644.
  • Reilly, M.P., Chomo, M.J., Obata, K. & Asakura, T. (1994) Red blood cell membrane and density changes under ambient and hypoxic conditions in transgenic mice producing human sickle hemoglobin. Experimental Hematology, 22, 501509.
  • Rogers, Z.R. (1997) Hydroxyurea therapy for diverse pediatric populations with sickle cell disease. Seminars in Hematology, 34, 4247.
  • Schechter, A.N., Noguchi, C.T. & Rogers, G.P. (1987) Sickle cell disease. In: The Molecular Basis of Blood Disease (ed. by G.Stanatyannopoules, A.W.Nienhuis, P.Leder & P.Majerus), p. 179. WB Saunders, Philadelphia.
  • Strand, L.P. & Scheline, R.R. (1975) The metabolism of vanillin and isovanillin in the rat. Xenobiotica, 5, 4963.
  • Uchida, K., Reilly, M.P. & Asakura, T. (1998) Molecular stability and function of mouse hemoglobins. Zoological Science, 15, 703706.
  • Vichinsky, E.P. (1997) Hydroxyurea in children: present and future. Seminars in Hematology, 34, 2229.
  • Zaugg, R.H., Walder, J.A. & Klotz, I.M. (1977) Schiff base adducts of hemoglobin. Modifications that inhibit erythrocyte sickling. Journal of Biological Chemistry, 252, 85428548.